Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1959
No trial phase data available
No trial data available
No trial data available
No approval data available
- A small-molecule compound called CPACC that blocks mitochondrial magnesium transport prevented obesity and liver damage in mice fed a long-term Western diet. - Mice lacking the MRS2 magnesium channel stayed lean, showed browning of white fat, and were protected from fatty liver disease and liver tumors. - CPACC injections every three days for six weeks limited weight gain and improved liver function markers in diet-challenged mice. - The findings point to mitochondrial magnesium channels as a novel therapeutic target for obesity, type 2 diabetes, fatty liver disease, and cardiometabolic conditions.
- Spark Biomedical has completed enrollment for two pivotal clinical trials investigating transcutaneous auricular neurostimulation (tAN) therapy for opioid use disorder in adults and neonatal opioid withdrawal syndrome. - The adult trial, funded by NIDA under the HEAL Initiative, examines whether wearable neurostimulation can improve treatment retention rates in patients with opioid use disorder, where relapse rates exceed 70%. - The pediatric trial focuses on newborns with neonatal opioid withdrawal syndrome, investigating whether tAN therapy combined with morphine treatment can reduce time to medical readiness for discharge. - Both studies represent potential breakthrough approaches to addressing the opioid crisis through non-invasive, drug-free neurostimulation technology that has received FDA Breakthrough Device Designation.
